Abivax

Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021

Retrieved on: 
Monday, October 18, 2021
MPS VI, Achievement, Lists of diseases, Gene expression, Fast track (FDA), Breakthrough therapy, Adult, Computational chemistry, Nasdaq, ISIN, PPAR, FDA, Liver disease, NASH, Government, Patient, Science, Abivax, AbbVie, Chronic liver disease, Degenerative disease, Biology, IVA, Company, Psoriasis, Factor X, MPS, Research, Pharmacokinetics, Pharmacology, Pharmaceutical industry

AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease.

Key Points: 
  • AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease.
  • AASLD fosters research that leads to improved treatment options for millions of liver disease patients.
  • We advance the science and practice of hepatology through educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies.
  • In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.

DGAP-News: ABIVAX: ABX464 shows excellent long-term efficacy data in Abivax's phase 2b maintenance Trial in ulcerative colitis

Retrieved on: 
Monday, October 18, 2021
EMA, Cancer, Ulcerative colitis, European Medicines Agency, ISIN, Hepatocellular carcinoma, JAK, PP, FDA, Volunteering, Patient, Abivax, UC, ITT, Twitter, Maintenance, Safety, Degenerative disease, Pharmaceutical industry, Medical device

During the induction and the maintenance phases of the phase 2b study, ABX464 continued to show a good safety and tolerability profile, confirming the data already generated in over 850 patients and volunteers treated with ABX464 so far.

Key Points: 
  • During the induction and the maintenance phases of the phase 2b study, ABX464 continued to show a good safety and tolerability profile, confirming the data already generated in over 850 patients and volunteers treated with ABX464 so far.
  • In May and September 2021, Abivax already announced the top-line and full results , respectively, of this randomized, placebo-controlled phase 2b trial of ABX464 in moderate to severe ulcerative colitis patients following induction treatment.
  • 254 patients with moderate to severe active ulcerative colitis were enrolled in this phase 2b trial and randomized to three once-daily oral ABX464 treatment groups (25mg, 50mg and 100mg) or placebo.
  • In addition to the phase 2b maintenance results, Abivax recently also reported efficacy data from its ongoing phase 2a maintenance study in UC.

DGAP-News: Abivax announces the release of its 2021 half-year financial report

Retrieved on: 
Thursday, September 30, 2021
ISIN, CEST, Abivax, Euronext Paris, Cancer, Patient, AMF, Immune system, Twitter, Hepatocellular carcinoma, Degenerative disease, Pharmaceutical industry

PARIS, France, September 30, 2021 - 6:00 pm (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publication of its 2021 half-year financial report.

Key Points: 
  • PARIS, France, September 30, 2021 - 6:00 pm (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publication of its 2021 half-year financial report.
  • This document is available in electronic version on the website of the company ( www.abivax.com - "Investors" ) and on the website of the French financial markets authority, AMF ( www.amf-france.org ).
  • Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer.
  • Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe chronic inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.

Abivax publishes a prospectus in the context of its capital increase and bonds offering

Retrieved on: 
Saturday, July 24, 2021
Hepatology, Abivax, Medical specialties, Infectious causes of cancer, Clinical medicine, Hepatocellular carcinoma, Medicine, Cancer

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer.
  • Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnmo: ABVX).
  • Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.

Prometheus Biosciences Announces Initiation of Global Phase 2 Clinical Trial of PRA023 in Moderate-to-Severe Ulcerative Colitis (UC)

Retrieved on: 
Monday, July 19, 2021
Medical specialties, Clinical medicine, Medicine, Autoimmune diseases, Abdominal pain, Colitis, Diarrhea, Ulcerative colitis, Crohn's disease, Monoclonal antibodies, Abivax, Draft:PPP001

The majority of patients with UC cannot achieve clinical remission through the use of currently available therapies, said Allison Luo, MD, Chief Medical Officer of Prometheus.

Key Points: 
  • The majority of patients with UC cannot achieve clinical remission through the use of currently available therapies, said Allison Luo, MD, Chief Medical Officer of Prometheus.
  • Prometheus has recently completed the dosing phase of the Phase 1a clinical trial of PRA023, a single center, double-blind, placebo-controlled trial to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRA023 in normal healthy volunteers.
  • Safety and tolerability observed to date supports the initiation of a Phase 2 trial.
  • Prometheus is developing PRA023 for the treatment of the two most common forms of IBD, Ulcerative Colitis (UC) and Crohns Disease (CD).

Inotrem Receives Approval to Expand Nangibotide Clinical Trial in Critically Ill COVID-19 Patients and Receives Additional Public Funding of €45 Million

Retrieved on: 
Monday, July 12, 2021
Health, Infectious diseases, Hospitals, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Nangibotide, Peptides, Medical research, Chemical compounds, Health sciences, Medicine, Abivax, COVID-19 drug repurposing research

This public funding will support Inotrems clinical program including the phase 2/3 study ESSENTIAL which aims to demonstrate the efficacy and safety of nangibotide in treating patients in respiratory distress with severe forms of COVID-19.

Key Points: 
  • This public funding will support Inotrems clinical program including the phase 2/3 study ESSENTIAL which aims to demonstrate the efficacy and safety of nangibotide in treating patients in respiratory distress with severe forms of COVID-19.
  • In ESSENTIAL, a Phase 2/3 clinical program, up to 730 patients will be enrolled initially in France and Belgium and, possibly in other European countries.
  • ESSNTIAL is the continuation of a 60 patients phase 2a evaluating the safety and efficacy of nangibotide in patients suffering from severe COVID-19.
  • Everyone at Inotrem is fully committed to deliver on this ambitious program alongside nangibotides ongoing Phase 2b trial in septic shock patients.

DGAP-News: Abivax reports excellent phase 2a clinical safety and efficacy results with 50mg ABX464 in rheumatoid arthritis

Retrieved on: 
Wednesday, June 23, 2021
Medical specialties, Clinical medicine, Medicine, Autoimmune diseases, Rheumatology, Immunosuppressants, Monoclonal antibodies, Abivax, Ulcerative colitis, Arthritis, Rheumatoid arthritis, Filgotinib, ABX464[8][9], Abivax (www.abivax.com), ABX464[8][9], ABIVAX (WWW.ABIVAX.COM)

The ACR20 is the key primary efficacy endpoint required by the FDA for licensure of new drugs in rheumatoid arthritis.

Key Points: 
  • The ACR20 is the key primary efficacy endpoint required by the FDA for licensure of new drugs in rheumatoid arthritis.
  • Based on these results, Abivax is preparing to start a clinical phase 2b program in RA in early 2022.
  • ABX464 was already shown to be efficacious and safe in phase 2a and phase 2b clinical studies for the treatment of ulcerative colitis (UC).
  • Therefore, the 100mg dose will not be considered for future clinical development of ABX464 in rheumatoid arthritis.

DGAP-News: Abivax releases the results of its June 4, 2021 ordinary annual and extraordinary general meeting

Retrieved on: 
Monday, June 7, 2021
Abivax, Corporate law, Shareholders, Extraordinary general meeting, Euronext, Hepatocellular carcinoma, Companies, Clinical medicine, Medicine

Abivax releases the results of its June 4, 2021 ordinary annual and extraordinary general meeting

Key Points: 
  • Abivax releases the results of its June 4, 2021 ordinary annual and extraordinary general meeting
    The issuer is solely responsible for the content of this announcement.
  • Abivax releases the results of its June 4, 2021 ordinary annual and extraordinary general meeting
    PARIS, France, June 7, 2021 - 6:00 pm (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, held its ordinary annual and extraordinary general meeting of shareholders on June 4, 2021, which was chaired by Philippe Pouletty, Chairman of the Board of directors, without the physical presence of the shareholders.
  • Shareholders also approved the reappointments of Philippe Pouletty, Truffle Capital, Sant Holding SRL and Corinna Zur Bonsen-Thomas as Board members.
  • Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.

DGAP-News: Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3

Retrieved on: 
Monday, May 24, 2021
Medical specialties, Clinical medicine, Medicine, Diarrhea, Monoclonal antibodies, Autoimmune diseases, Immunosuppressants, Colitis, Ulcerative colitis, Abivax, Vedolizumab, ABX464[9][10], Abivax (www.abivax.com), ABX464[9][10], ABIVAX (WWW.ABIVAX.COM)

254 patients with moderate to severe ulcerative colitis (UC) were treated with ABX464, a small molecule for once-daily administration with a first-in-class mechanism of action.

Key Points: 
  • 254 patients with moderate to severe ulcerative colitis (UC) were treated with ABX464, a small molecule for once-daily administration with a first-in-class mechanism of action.
  • The top-line data showed significant clinical efficacy in the overall patient population on primary and key secondary endpoints and a good safety profile of ABX464 during 8 weeks of induction treatment.
  • The phase 3 clinical program with ABX464 in UC is expected to start by year end.
  • I am looking forward to further support the planned phase 3 ulcerative colitis program as principal investigator."

DGAP-News: Abivax reports 2020 financial results and operations update

Retrieved on: 
Wednesday, March 31, 2021
Medical specialties, Hepatology, Abivax, Clinical medicine, Medicine, Hepatocellular carcinoma, Autoimmune diseases

These results confirmed the good safety profile and durable efficacy of 50 mg once-daily oral ABX464 in patients with moderate-to-severe UC.

Key Points: 
  • These results confirmed the good safety profile and durable efficacy of 50 mg once-daily oral ABX464 in patients with moderate-to-severe UC.
  • The recruitment of 254 patients within the induction study was achieved in December 2020.
  • There were approximately 3.8M diagnosed cases of RA in G7 countries in 2020, representing a market potential of about USD 20.2B.
  • Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.